We develop innovative therapeutics to protect and improve the vision of patients with a range of retinal diseases and conditions.
Learn More

ONL Therapeutics is a clinical-stage biopharmaceutical company committed to helping patients see the future.

Clinical Trials

The company’s lead therapeutic candidate, ONL1204, is a first-in-class small peptide that is being studied in multiple diseases.

Science

Our primary scientific focus is Fas-mediated signaling, initiated by the activation of the Fas receptor at the cell surface and implicated in a variety of diseases.

Month: January 2025

  • ONL Therapeutics Appoints Penny Fleck as Chief Development Officer

    ONL Therapeutics Appoints Penny Fleck as Chief Development Officer ANN ARBOR, Mich., January 7, 2025 – ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, today announced the appointment of Penny Fleck as chief development officer. In this role, Ms. Fleck will be responsible for…